Abstract
In the last few years, there have been significant advances in cancer agent research, most of which entered clinical trials after succeeding in initial preclinical studies. Here, we discuss successful accomplishments in the promising approaches of targeted therapies, immunotherapies, and combination therapies. The development in these areas includes sotorasib - targeting the mutation of KRAS for lung and pancreatic cancer and pembrolizumab - an immune checkpoint inhibitor for melanoma therapy; the latter has been synergistic with chemotherapy. In addition, exciting results emerge from trials with the DNA damage repair inhibitor olaparib in BRCA-mutated cancers and the tyrosine kinase inhibitor osimertinib for EGFR-mutant lung cancer. Bevacizumab continues to establish itself as an evolving therapy in colorectal cancer, and niraparib enters Phase III in ovarian cancer. New combinations will include alpelisib and PD-1 inhibitors and nanoparticle-based Abraxane for triple-negative breast cancers leading toward precision medicine. These would improve the survival rates and quality of life in patients with advanced or refractory malignancies.
© 2025 Bentham Science Publishers
Article metrics loading...
/content/journals/ccand/10.2174/012212697X361870250113043318
2025-01-14
2025-04-23
-
/content/journals/ccand/10.2174/012212697X361870250113043318
dcterms_title,dcterms_subject,pub_keyword
-contentType:Contributor -contentType:Concept -contentType:Institution
10
5
Full text loading...
[Citing articles]
[Web of Science]
[Medline]
References
-
Dwivedi
S.
Purohit
P.
Misra
R.
Lingeswaran
M.
Vishnoi
J.R.
Pareek
P.
Barh
D.
Azevedo
V.
Application of single-cell omics in breast cancer.
Academic Press
Single-cell omics.
2019
69
103
10.1016/B978‑0‑12‑817532‑3.00005‑0
-
[Google Scholar]
-
Dwivedi
S.
Purohit
P.
Misra
R.
Lingeswaran
M.
Vishnoi
J.R.
Pareek
P.
Misra
S.
Sharma
P.
Single cell omics of breast cancer: An update on characterization and diagnosis.
Indian J. Clin. Biochem.
2019
34
1
3
18
10.1007/s12291‑019‑0811‑0
30728668
-
Strickler
J.H.
Satake
H.
George
T.J.
Yaeger
R.
Hollebecque
A.
Garrido-Laguna
I.
Schuler
M.
Burns
T.F.
Coveler
A.L.
Falchook
G.S.
Vincent
M.
Sunakawa
Y.
Dahan
L.
Bajor
D.
Rha
S.Y.
Lemech
C.
Juric
D.
Rehn
M.
Ngarmchamnanrith
G.
Jafarinasabian
P.
Tran
Q.
Hong
D.S.
Sotorasib in KRAS p.G12C–mutated advanced pancreatic cancer.
N. Engl. J. Med.
2023
388
1
33
43
10.1056/NEJMoa2208470
36546651
-
Chesney
J.A.
Ribas
A.
Long
G.V.
Kirkwood
J.M.
Dummer
R.
Puzanov
I.
Hoeller
C.
Gajewski
T.F.
Gutzmer
R.
Rutkowski
P.
Demidov
L.
Arenberger
P.
Shin
S.J.
Ferrucci
P.F.
Haydon
A.
Hyngstrom
J.
van Thienen
J.V.
Haferkamp
S.
Guilera
J.M.
Rapoport
B.L.
VanderWalde
A.
Diede
S.J.
Anderson
J.R.
Treichel
S.
Chan
E.L.
Bhatta
S.
Gansert
J.
Hodi
F.S.
Gogas
H.
Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma.
J. Clin. Oncol.
2023
41
3
528
540
10.1200/JCO.22.00343
35998300
-
Nambiar
D.K.
Mishra
D.
Singh
R.P.
Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials.
Oncol. Res.
2023
31
4
405
421
10.32604/or.2023.028310
37415740
-
Cheng
Z.
Cui
H.
Wang
Y.
Yang
J.
Lin
C.
Shi
X.
Zou
Y.
Chen
J.
Jia
X.
Su
L.
The advance of the third‑generation EGFR‑TKI in the treatment of non‑small cell lung cancer (Review).
Oncol. Rep.
2023
51
1
16
10.3892/or.2023.8675
38063215
-
Song
Y.
Mao
Q.
Zhou
M.
Liu
C.J.
Kong
L.
Hu
T.
Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: A systematic review and meta-analysis.
BMC Gastroenterol.
2024
24
1
58
10.1186/s12876‑024‑03134‑w
38302922
-
Lim
A.R.
Kim
B.
Kim
J.H.
Hyun
M.H.
Park
K.H.
Kim
Y.H.
Lee
S.
Phase Ib and pharmacokinetics study of alpelisib, a PIK3CA inhibitor, and capecitabine in patients with advanced solid tumors.
Front. Oncol.
2024
14
1390452
10.3389/fonc.2024.1390452
39070139
-
Wang
X.
Zhao
S.
Xin
Q.
Zhang
Y.
Wang
K.
Li
M.
Recent progress of CDK4/6 inhibitors’ current practice in breast cancer.
Cancer Gene Ther.
2024
31
9
1283
1291
10.1038/s41417‑024‑00747‑x
38409585
-
Hu
D.
Cao
J.
Yu
H.
Ding
N.
Mi
L.
Ye
Y.
Li
M.
Wang
D.
Wu
J.
Wang
X.
Song
Y.
Zhu
J.
Ping
L.
PI3K inhibitor idelalisib enhances the anti-tumor effects of CDK4/6 inhibitor palbociclib
via PLK1 in B-cell lymphoma.
Cancer Lett.
2024
597
216996
10.1016/j.canlet.2024.216996
38815797
-
Shimoi
T.
Sunami
K.
Tahara
M.
Nishiwaki
S.
Tanaka
S.
Baba
E.
Kanai
M.
Kinoshita
I.
Shirota
H.
Hayashi
H.
Nishida
N.
Kubo
T.
Mamesaya
N.
Ando
Y.
Okita
N.
Shibata
T.
Nakamura
K.
Yamamoto
N.
Dabrafenib and trametinib administration in patients with
BRAF V600E/R or non-V600
BRAF mutated advanced solid tumours (BELIEVE, NCCH1901): A multicentre, open-label, and single-arm phase II trial.
EClinicalMedicine
2024
69
102447
10.1016/j.eclinm.2024.102447
38333370
-
Leena Panigrahi
L.
Samal
P.
Ranjan Sahoo
S.
Sahoo
B.
Pradhan
A.K.
Mahanta
S.
Rath
S.K.
Arakha
M.
Nanoparticle-mediated diagnosis, treatment, and prevention of breast cancer.
Nanoscale Adv.
2024
6
15
3699
3713
10.1039/D3NA00965C
-
Sreekumar
S.
Montaudon
E.
Klein
D.
Gonzalez
M.E.
Painsec
P.
Derrien
H.
Sourd
L.
Smeal
T.
Marangoni
E.
Ridinger
M.
PLK1 Inhibitor Onvansertib enhances the efficacy of alpelisib in PIK3CA-mutated HR-positive breast cancer resistant to palbociclib and endocrine therapy: preclinical insights.
Cancers
2024
16
19
3259
10.3390/cancers16193259
39409880
/content/journals/ccand/10.2174/012212697X361870250113043318
